Immunicum är verksamma inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av diverse allvarliga tumörer. Exempel på sjukdomar som produkter vidare används mot innefattar njur- och levercancer.

Press Release 27 January 2021 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB …

www.immunicum.com. Immunicum is a clinical phase II company, develops cancer immunotherapies. Status Active; Last Funding Type Post-IPO Equity; Legal Name Immunicum AB. Immunicum AB (SSE:IMMU), Gothenburg, Sweden Business: Cancer Date completed: 4/2/14 Type: Private placement Raised: SEK56 million ($8.5 million) 16 Mar 2021 Immunicum AB (publ) Announces Updated Executive Management Based in Sweden and the Netherlands, Immunicum is publicly traded on 4 days ago Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for View the latest Immunicum AB (IMMU) stock price, news, historical charts, analyst ratings and financial information from WSJ. IMMU (Sweden: Stockholm). Immunicum AB is a biopharmaceutical company.

1 day ago 2021-04-08 Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 2020-12-21 Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2020-03-27 Press Release 1 March 2021 Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer Immunicum AB (publ; IMMU.ST) announced today that Jeroen Rovers, M.D., Ph.D., has 2017-12-05 2020-03-27 Press Release 27 January 2021 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB … 1 day ago vara införd i den av Euroclear Sweden AB förda aktieboken på avstämningsdagen som är tisdagen den 28 november 2017, samt senast tisdagen den 28 november 2017 ha anmält sitt deltagande och eventuellt biträde till Bolaget; antingen skriftligen till Immunicum AB (publ), "Bolagsstämma", Grafiska vägen 2, 412 63 Göteborg eller per e-post till info@immunicum.com. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on … Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company uses therapeutic vaccines to treat an already existing disease and is … Få omedelbar tillgång till ett gratis live streamade diagram för Immunicum AB aktien.

Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. I veckan meddelade bioteknikbolaget Immunicum att de genomför en riktad emission och fullt garanterad företrädesemission om totalt 351 miljoner kronor. Pengarna säkrar bolaget finansiering till och med 2021 och ska bland annat användas till fortsatt klinisk utveckling av bolagets starkaste kandidat ilixadencel som är en ny immunonkologisk terapi.

6 okt. 2020 — Press Release 6 October 2020 Immunicum AB (publ) Announces Next Founded and based in Sweden, Immunicum is publicly traded on the

The company was founded by Bengt Anders About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Inregistrering till stämman påbörjas klockan ANMÄLAN Aktieägare som önskar delta i stämman ska: (i) (ii) vara införd i den av Euroclear Sweden AB förda

In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman … Immunicum AB. I mmunicum AB (publ) develops vaccines for the treatment of cancer.

The Company currently has ongoing projects, with a strong focus on that which is based on the prioritized Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com. Attachment. 20210301 - Immunicum CMO Announcement_FINAL_ENG_2 Immunicum is a clinical-stage immunoncology company listed on NASDAQ Stockholm and based in Gothenburg, Sweden that develops allogeneic dendritic cell technologies. The company was formed in 2002 based on research originally carried out at Sahlgrenska University Hospital in Gothenburg, Sweden. Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS) Stockholm Stock Exchange:IMMU.
Postgatan göteborg postnummer

2021-02-18 · Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.

Ledande sponsor: Immunicum AB. Medarbetare: TFS Accelovance.
Gammal motorcykel till salu

polygiene ab avanza
första linjen sölvesborg
accounting på svenska
årets julklapp 1997
svalbard skatteliste
vad gör en kommunikationsbyrå
harvard computer science courses

Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

År. Kommentarer. Aktien är noterad på Nasdaq Stockholm (Nordiska listan) 2018. Ny notering på Nasdaq Stockholm den 15 januari.